missing translation for 'onlineSavingsMsg'
Learn More
Learn More
CD11b Rat anti-Mouse, PE, Clone: M1/70, BD
Rat Monoclonal Antibody
Marca: BD Biosciences 561689
Codice prodotto. 15841239
-
74.90€
70.00€ / Pezzo
Risparmia 4.90€
6% Sconto
Effettua il login per acquistare questo articolo Hai bisogno di un conto web ? Registrati oggi stesso!
Questo articolo non è restituibile.
Consulta la politica di reso
Descrizione
The M1/70 antibody reacts with the 170kDa α[M] chain of Mac-1 (CD11b/CD18, α[M]β2 integrin), also known as complement receptor 3 (CR3), which mediates adhesion to C3bi and ICAM-1 (CD54). Mac-1 is expressed at varying levels on granulocytes, macrophages, myeloid-derived dendritic cells, natural killer cells, microglia, and B-1 cells. Mac-1 expression is rapidly up-regulated on neutrophils after activation, in the same time period that CD62L (L-selectin) is shed from the cell surface. M1/70 antibody reportedly blocks cell adherence and C3bi binding, but it does not block cell-mediated lysis. Cross-reaction of mAb M1/70 with CD11b on human monocytes, polymorphonuclear leukocytes, and NK cells has been reported. This antibody is routinely tested by flow cytometric analysis. Other applications were tested at BD Biosciences Pharmingen during antibody development only or reported in the literature.
Host Species: Rat
Clone: M1/70
Isotype: IgG2b, κ
Cross Reactivity: Mouse
Flow Cytometry
Specifica
| CD11b | |
| Monoclonal | |
| 0.2mg/mL | |
| Itgam; Integrin alpha-M; Ly-40; Mac-1a; Mac-1 alpha; CR3A; CR-3 alpha chain | |
| Rat | |
| Affinity Purified | |
| RUO | |
| Human, Mouse | |
| IgG2b κ |
| Flow Cytometry | |
| M1/70 | |
| PE | |
| Aqueous buffered solution containing ≤0.09% sodium azide. | |
| Mouse Splenic Cells | |
| 25 μg | |
| Primary | |
| Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. |
Correzione del contenuto del prodotto
Fornite il vostro feedback sul contenuto del prodotto compilando il modulo sottostante.
Titolo del prodotto
For Research Use Only.
Individuate un'opportunità di miglioramento?Condividi una correzione di contenuto